Aardvark Therapeutics (AARD) Competitors $11.29 -0.48 (-4.08%) As of 06/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD vs. SYRE, CVAC, AKBA, PAHC, SNDX, NRIX, COLL, AVDL, QURE, and NAGEShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Spyre Therapeutics (SYRE), CureVac (CVAC), Akebia Therapeutics (AKBA), Phibro Animal Health (PAHC), Syndax Pharmaceuticals (SNDX), Nurix Therapeutics (NRIX), Collegium Pharmaceutical (COLL), Avadel Pharmaceuticals (AVDL), uniQure (QURE), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Its Competitors Spyre Therapeutics CureVac Akebia Therapeutics Phibro Animal Health Syndax Pharmaceuticals Nurix Therapeutics Collegium Pharmaceutical Avadel Pharmaceuticals uniQure Niagen Bioscience Spyre Therapeutics (NASDAQ:SYRE) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Does the media favor SYRE or AARD? In the previous week, Aardvark Therapeutics had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 4 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.12 beat Aardvark Therapeutics' score of 1.08 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, SYRE or AARD? Aardvark Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,219.07-$338.79M-$3.77-4.77Aardvark TherapeuticsN/AN/AN/AN/AN/A Do institutionals & insiders have more ownership in SYRE or AARD? 80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.4% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is SYRE or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -210.01% -44.40% Aardvark Therapeutics N/A N/A N/A Do analysts recommend SYRE or AARD? Spyre Therapeutics presently has a consensus target price of $53.40, indicating a potential upside of 196.67%. Aardvark Therapeutics has a consensus target price of $31.25, indicating a potential upside of 176.79%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Spyre Therapeutics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor SYRE or AARD? Spyre Therapeutics received 14 more outperform votes than Aardvark Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Spyre Therapeutics an outperform vote while only 80.00% of users gave Aardvark Therapeutics an outperform vote. CompanyUnderperformOutperformSpyre TherapeuticsOutperform Votes22100.00% Underperform VotesNo VotesAardvark TherapeuticsOutperform Votes880.00% Underperform Votes220.00% SummarySpyre Therapeutics beats Aardvark Therapeutics on 10 of the 13 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$244.95M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.7827.1320.06Price / SalesN/A255.64412.28157.10Price / CashN/A65.8538.2534.64Price / BookN/A6.557.064.70Net IncomeN/A$143.93M$3.23B$247.88M7 Day Performance-5.52%3.84%2.86%2.63%1 Month Performance2.92%11.20%9.05%6.36%1 Year PerformanceN/A4.18%31.39%14.05% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$11.29-4.1%$31.25+176.8%N/A$244.95MN/A0.0018Analyst RevisionGap UpSYRESpyre Therapeutics2.4074 of 5 stars$16.62+0.6%$53.40+221.3%-52.6%$1.00B$890K-2.2273Positive NewsCVACCureVac4.4171 of 5 stars$4.46+0.5%$11.00+146.6%-4.2%$1.00B$523.70M8.11880Positive NewsAKBAAkebia Therapeutics4.4693 of 5 stars$3.69+1.4%$6.75+82.9%+221.6%$969.13M$184.91M-16.04430PAHCPhibro Animal Health3.8832 of 5 stars$23.89-0.3%$20.00-16.3%+45.6%$968.36M$1.19B49.771,860Positive NewsSNDXSyndax Pharmaceuticals3.0257 of 5 stars$11.16+1.8%$35.91+221.8%-43.6%$960.29M$43.72M-3.07110Positive NewsNRIXNurix Therapeutics2.1499 of 5 stars$12.50+2.8%$30.18+141.4%-21.8%$952.95M$56.42M-4.33300Positive NewsGap UpCOLLCollegium Pharmaceutical4.0333 of 5 stars$29.50+0.3%$43.80+48.5%-8.8%$947.89M$664.28M12.72210Positive NewsInsider TradeAVDLAvadel Pharmaceuticals2.1754 of 5 stars$9.44+1.4%$19.43+105.8%-35.2%$913.22M$194.45M-11.9570Positive NewsAnalyst RevisionQUREuniQure2.0725 of 5 stars$16.61+11.0%$37.82+127.7%+210.1%$909.83M$20.20M-3.35500News CoverageAnalyst RevisionNAGENiagen Bioscience1.5046 of 5 stars$11.51-1.8%$13.00+12.9%N/A$906.64M$107.93M67.71120News CoverageAnalyst Forecast Related Companies and Tools Related Companies SYRE Alternatives CVAC Alternatives AKBA Alternatives PAHC Alternatives SNDX Alternatives NRIX Alternatives COLL Alternatives AVDL Alternatives QURE Alternatives NAGE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AARD Stock Free AARD Stock Alerts